New Complementary Diagnostic Test Available from LabCorp for Treatment of Bladder Cancer
May 19 2016 - 8:45AM
Business Wire
VENTANA PD-L1 (SP142) Assay Identifies
Metastatic Patients with Urothelial Cancer that May Benefit from
Treatment with TECENTRIQ® (atezolizumab)
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH)
today announced the nationwide availability of the VENTANA PD-L1
(SP142) Assay as a complementary diagnostic for TECENTRIQ
(atezolizumab), a new immunotherapy treatment for patients with
urothelial cancer, the most common form of bladder cancer in the
U.S. The test was developed by Roche Diagnostics and was approved
on May 18, 2016 by the U.S. Food and Drug Administration (FDA) to
identify patients who may benefit from treatment with Genentech’s
TECENTRIQ (atezolizumab). The availability of this important new
test demonstrates LabCorp’s commitment to provide world-class
diagnostics to physicians and their patients.
“LabCorp is dedicated to improving health and improving lives
through the introduction of new tests and by bringing innovative
medicines to patients faster,” said David P. King, LabCorp’s
chairman and chief executive officer. “LabCorp is particularly
focused on the development of immunotherapies and tests that pair
with these medicines to change the way care is provided to cancer
patients, and we are pleased to be among the first laboratories to
offer the VENTANA PD-L1 (SP142) assay.”
Bladder cancer is the most common malignancy of the urinary
system and the ninth most common form of cancer worldwide. Despite
urothelial (transitional cell) cancer being the most common form of
bladder cancer in the U.S., no major new therapies have been
introduced for it in the past 30 years. The availability of
TECENTRIQ in combination with the PD-L1 (SP142) test has the
potential to significantly improve the treatment of patients
diagnosed with this form of cancer. In addition to identifying the
PD-L1 protein on tumor infiltrating immune cells, the assay also
offers a novel immune cell scoring algorithm that can aid
physicians to identify patients for whom treatment with TECENTRIQ
may be the right option.
“LabCorp already offers companion diagnostic and complementary
diagnostic tests to help identify patients who may benefit from
new, targeted immunotherapies for the treatment of melanoma and
lung cancer,” said Dr. Mark Brecher, LabCorp’s chief medical
officer. “The PD-L1 (SP142) assay can help change the way care is
provided by helping physicians better understand the potential
benefits of treatment with TECENTRIQ for their patients with
bladder cancer.”
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through
LabCorp Diagnostics, and end-to-end drug development support
through Covance Drug Development. LabCorp is a pioneer in
commercializing new diagnostic technologies and is improving
people’s health by delivering the combination of world-class
diagnostics, drug development services and technology-enabled
solutions. With net revenue in excess of $8.5 billion in 2015 and
more than 50,000 employees in approximately 60 countries, LabCorp
offers innovative solutions to healthcare stakeholders. LabCorp
clients include physicians, patients and consumers,
biopharmaceutical companies, government agencies, managed care
organizations, hospitals, and clinical labs. To learn more about
Covance Drug Development, visit www.covance.com. To learn more
about LabCorp and LabCorp Diagnostics, visit www.labcorp.com.
This press release contains forward-looking statements including
with respect to estimated 2016 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace, adverse actions of governmental and other third-party
payers and the results from the Company’s acquisition of Covance.
Actual results could differ materially from those suggested by
these forward-looking statements. Further information on potential
factors that could affect LabCorp’s operating and financial results
is included in the Company’s Form 10-K for the year ended December
31, 2015, and subsequent Forms 10-Q, including in each case under
the heading risk factors, and in the Company’s other filings with
the SEC, as well as in the risk factors included in Covance’s
filings with the SEC. The information in this press release should
be read in conjunction with a review of the Company’s filings with
the SEC including the information in the Company’s Form 10-K for
the year ended December 31, 2015, and subsequent Forms 10-Q, under
the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160519005410/en/
Laboratory Corporation of America® HoldingsInvestors:Paul
Surdez, 336-436-5076Investor@labcorp.comorMedia:Pattie Kushner,
336-436-8263Media@labcorp.com
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024